Soon-Tae Lee1, Chul-Kee Park1, Jin Wook Kim1, Min-Jung Park1, Hyon Lee1, Jung-Ah Lim1, Seung Hong Choi1, Tae Min Kim1, Se-Hoon Lee1, Sung-Hye Park1, Il Han Kim1, Kyoung-Min Lee1. 1. Department of Neurology, Seoul National University Hospital, Seoul, Korea (S.-T.L., H.L., J.-A.L., K.-M.L.); Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea (C.-K.P., J.W.K., M.-J.P.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (S.H.C.); Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea (T.M.K., S.-H.L.); Department of Pathology, Seoul National University Hospital, Seoul, Korea (S.-H.P.); Department of Radiation Oncology,Seoul National University Hospital, Seoul, Korea (I.H.K.).
Abstract
BACKGROUND: Early progression of glioblastoma prevents patients from completing the standard chemoradiation protocol. Given that cognitive function is associated with prognosis in glioblastoma, we investigated the usefulness of preoperative cognitive function tests for predicting the early progression of glioblastoma. METHODS: Consecutive patients who underwent glioma surgery were preoperatively evaluated with cognitive function tests including the Mini Mental State Examination, digit span tests, the Controlled Oral Word Association Test, the Trail Making Tests (TMT, parts A, B, and C), and the Stroop test. Glioblastomas were treated with a standard protocol using radiation and temozolomide, and 6-month progression-free survival (PFS-6) was analyzed retrospectively. RESULTS: Among 126 patients who underwent glioma surgery, 55 patients were diagnosed with glioblastoma, and 50 patients were eligible for the PFS-6 analysis. Thirty-four patients (68%) achieved PFS-6. No significant differences were observed in demographics or tumor characteristics between patients without progression (PFS-6) or patients with progression (no-PFS-6). In the cognitive function tests, the PFS-6 patients exhibited better performance in TMT-A and TMT-B. In a multivariate logistic regression, TMT-B was the only independent predictor for PFS-6, whereas age, years of education, gross total or near total resection, concomitant chemoradiation, and TMT-A were not predictors. Patients with good TMT-B performance exhibited better early prognosis in the Kaplan-Meier survival analysis and had better recursive partitioning analysis classes. CONCLUSIONS: Our results indicated that preoperative TMTs can be useful for rapid evaluation of early prognosis in patients with glioblastoma.
BACKGROUND: Early progression of glioblastoma prevents patients from completing the standard chemoradiation protocol. Given that cognitive function is associated with prognosis in glioblastoma, we investigated the usefulness of preoperative cognitive function tests for predicting the early progression of glioblastoma. METHODS: Consecutive patients who underwent glioma surgery were preoperatively evaluated with cognitive function tests including the Mini Mental State Examination, digit span tests, the Controlled Oral Word Association Test, the Trail Making Tests (TMT, parts A, B, and C), and the Stroop test. Glioblastomas were treated with a standard protocol using radiation and temozolomide, and 6-month progression-free survival (PFS-6) was analyzed retrospectively. RESULTS: Among 126 patients who underwent glioma surgery, 55 patients were diagnosed with glioblastoma, and 50 patients were eligible for the PFS-6 analysis. Thirty-four patients (68%) achieved PFS-6. No significant differences were observed in demographics or tumor characteristics between patients without progression (PFS-6) or patients with progression (no-PFS-6). In the cognitive function tests, the PFS-6 patients exhibited better performance in TMT-A and TMT-B. In a multivariate logistic regression, TMT-B was the only independent predictor for PFS-6, whereas age, years of education, gross total or near total resection, concomitant chemoradiation, and TMT-A were not predictors. Patients with good TMT-B performance exhibited better early prognosis in the Kaplan-Meier survival analysis and had better recursive partitioning analysis classes. CONCLUSIONS: Our results indicated that preoperative TMTs can be useful for rapid evaluation of early prognosis in patients with glioblastoma.
Entities:
Keywords:
6-month progression-free survival; cognitive function test; glioblastoma; trail making test
Authors: Ingeborg Bosma; Maaike J Vos; Jan J Heimans; Martin J B Taphoorn; Neil K Aaronson; Tjeerd J Postma; Henk M van der Ploeg; Martin Muller; W Peter Vandertop; Ben J Slotman; Martin Klein Journal: Neuro Oncol Date: 2006-10-03 Impact factor: 12.300
Authors: Paul D Brown; Ashley W Jensen; Sara J Felten; Karla V Ballman; Paul L Schaefer; Kurt A Jaeckle; Jane H Cerhan; Jan C Buckner Journal: J Clin Oncol Date: 2006-12-01 Impact factor: 44.544
Authors: M Klein; M J Taphoorn; J J Heimans; H M van der Ploeg; W P Vandertop; E F Smit; S Leenstra; C A Tulleken; W Boogerd; J S Belderbos; W Cleijne; N K Aaronson Journal: J Clin Oncol Date: 2001-10-15 Impact factor: 44.544
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Elke Butterbrod; Jimme Bruijn; Meriam M Braaksma; Geert-Jan M Rutten; Cees C Tijssen; Monique C J Hanse; Margriet M Sitskoorn; Karin Gehring Journal: J Neurooncol Date: 2019-07-24 Impact factor: 4.130